Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $5.0 million.

  • China Pharma Holdings' Total Current Liabilities rose 39.13% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 39.13%. This contributed to the annual value of $5.0 million for FY2024, which is 26.44% down from last year.
  • Per China Pharma Holdings' latest filing, its Total Current Liabilities stood at $5.0 million for FY2024, which was down 26.44% from $6.8 million recorded in FY2023.
  • China Pharma Holdings' Total Current Liabilities' 5-year high stood at $12.7 million during FY2022, with a 5-year trough of $5.0 million in FY2024.
  • For the 3-year period, China Pharma Holdings' Total Current Liabilities averaged around $8.2 million, with its median value being $6.8 million (2023).
  • In the last 5 years, China Pharma Holdings' Total Current Liabilities grew by 21.17% in 2022 and then slumped by 46.46% in 2023.
  • China Pharma Holdings' Total Current Liabilities (Yearly) stood at $11.4 million in 2020, then fell by 7.81% to $10.5 million in 2021, then grew by 21.17% to $12.7 million in 2022, then tumbled by 46.46% to $6.8 million in 2023, then declined by 26.44% to $5.0 million in 2024.